American Society of Hirudotherapy

Survival Differences in Women with and without Autologous Breast Reconstruction after Mastectomy for Breast Cancer

Research article published in Plastic and reconstructive surgery. Global open (2017)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportClinical TrialsL et al. · Plastic and reconstructive surgery. Global open, 2017

Abstract

BACKGROUND: Breast reconstruction (BR) is an option for women who are treated with mastectomy; however, there has been concern regarding the oncologic safety of BR. In this study, we evaluated recurrences and mortality in women treated with mastectomy and compared outcomes in those treated with mastectomy alone to those with mastectomy plus transverse rectus adbominis (TRAM) flap BR. METHODS: The prospective cohort study included women treated with mastectomy at Women's College Hospital from 1987 to 1997. Women with TRAM flap BR were matched to controls based on age and year of diagnosis, stage, and nodal status. Patients were followed from the date of diagnosis until death or date of last follow-up. Hazard ratios were generated to compare cases and controls for outcome variables using Cox's proportional hazards models. RESULTS: Of 443 women with invasive breast cancer, 85 subjects had TRAM flap BR. Sixty-five of these women were matched to 115 controls. The mean follow-up was 11.2 (0.4-26.3) years. There were no significant differences between those with and without BR with weight, height, or smoking status. Women with TRAM flap were less likely to experience a distant recurrence compared to women without a TRAM flap (relative risk, 0.42; P = 0.0009) and were more likely to be alive (relative risk, 0.54; P = 0.03). CONCLUSIONS: Women who elect for TRAM flap BR after an invasive breast cancer diagnosis do have lower rates of recurrences and mortality than women treated with mastectomy alone. This cannot be explained by differences in various clinical or lifestyle factors.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article

Summary

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Why This Matters for Hirudotherapy

This Plastic and Reconstructive Surgery Global Open (2017) prospective matched cohort study evaluated oncologic safety of autologous breast reconstruction by comparing women treated with mastectomy alone to those with mastectomy plus TRAM flap reconstruction at a single hospital (1987-1997); per the abstract, among matched patients (65 with TRAM flap, 115 controls, mean follow-up 11.2 years) women with TRAM flap reconstruction had lower distant recurrence (relative risk 0.42, P=0.0009) and higher survival (relative risk 0.54, P=0.03), not explained by measured clinical or lifestyle factors. It is relevant to hirudotherapy as context on TRAM flap reconstruction, a flap type whose postoperative venous congestion is an indication for the FDA-cleared medicinal leech, framing the clinical population in which such flaps are used. Caveat: this is an observational matched cohort, not a randomized trial, so the authors' association between reconstruction and improved survival is subject to residual confounding and selection effects and does not establish causation; the study does not address venous congestion or hirudotherapy.

Citation

Survival Differences in Women with and without Autologous Breast Reconstruction after Mastectomy for Breast Cancer.

L et al. · Plastic and reconstructive surgery. Global open, 2017

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.